No profile data available.
Traws Pharma, Inc. (TRAW) is a healthcare company in the additional cancer treatment drugs industry, based in Newtown, United States, with about 4 full-time employees.
It reported revenue of $2.79 million for fiscal year 2025, up 1134.5% from fiscal year 2024, and net income of $6.87 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $6.84 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer.
Traws Pharma reported $2.79 million in revenue for fiscal year 2025, up 1134.5% from $226,000 in fiscal year 2024. In Q2 2026 revenue was $0.
$6.84 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Bolt Biotherapeutics, Inc. (BOLT), CNS Pharmaceuticals, Inc. (CNSP), Aprea Therapeutics, Inc. (APRE), Imunon, Inc. (IMNN).